Filing summary
Entity and period: The source filing is for IsoRay, Inc. and its subsidiaries, not Perspective Therapeutics, Inc. It is a Form 10-Q for the fiscal quarter and six months ended December 31, 2014, with comparisons to the corresponding 2013 periods. IsoRay sells brachytherapy products, including Cesium-131 seeds and the GliaSite Radiation Therapy System.
Financial results
| Metric | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Product sales | $1.066 million | $2.108 million | $1.085 million quarterly; $2.135 million six-month |
| Gross loss | $38,000 | $93,000 | $34,000 quarterly; $111,000 six-month |
| Operating loss | $1.020 million | $2.181 million | $1.044 million quarterly; $2.279 million six-month |
| Net loss | $907,000 | $1.693 million | $927,000 quarterly; $2.198 million six-month |
| Net loss applicable to common shareholders | $910,000 | $1.698 million | $930,000 quarterly; $2.930 million six-month |
| Basic and diluted loss per share | $(0.02) | $(0.03) | $(0.02) quarterly; $(0.08) six-month |
| Net cash used by operating activities | Not separately stated | $1.758 million | $1.738 million six-month |
- Margins: Gross margin remained negative: approximately 4% below zero for the six-month period, versus approximately 5% below zero in 2013. The quarterly reported gross loss percentage was approximately 4%, versus 3% in 2013.
- Liquidity: At December 31, 2014, cash and cash equivalents were $1.337 million, current certificates of deposit were $10.047 million, and non-current certificates were $10.097 million. Cash plus certificates of deposit totaled approximately $21.5 million. Total current assets were $12.825 million and current liabilities $942,000; total assets were $24.585 million.
- Debt and liabilities: The balance sheet reports no conventional borrowings. Total liabilities were $2.057 million, including a $209,000 warrant derivative liability and a $906,000 asset retirement obligation.
- Cash flows: Investing activities used $4.791 million, principally reflecting certificate-of-deposit purchases and maturities; this should not be read as equivalent to operating cash burn. Financing provided $205,000, mainly from warrant and option exercises.
Changes versus prior period
- Six-month sales declined 1%. Prostate sales rose 2%, while other product sales fell 20%, largely due to lower GliaSite sales, particularly to foreign distributors. Quarterly sales declined 2%.
- The top five customers accounted for 62% of quarterly revenue, up from 52%; for the six-month period, the five largest users represented 57% versus 59% in 2013. This indicates meaningful customer concentration.
- Six-month gross loss improved by $18,000 as cost of sales declined more than revenue. Operating loss improved by $97,000, while operating cash use increased by $20,000.
- Six-month net loss improved, partly because the noncash gain from changes in warrant fair value was $347,000, compared with $81,000 in 2013, and interest income rose to $145,000 from $835. The common-shareholder loss comparison also reflects a $726,000 preferred-stock deemed dividend in 2013.
Outlook, risks, and unusual items
- Management estimated monthly cash operating expenditures at approximately $294,000 and stated that available cash and certificates of deposit should fund anticipated needs for at least five years, assuming revenue and expenses remain at current levels. This is management’s estimate, not a guarantee.
- Management expected fiscal 2015 protocol expenses of approximately $180,000 and less than $50,000 in capital spending for liquid Cesium-131 production, while noting that additional needs could arise. It aimed to reach breakeven through customer growth, GliaSite sales, and new treatment applications, but acknowledged no assurance of profitability and that prostate sales had not achieved the growth needed to break even.
- Management cited pressure on prostate brachytherapy from competing treatments and reimbursement, slow facility and regulatory approvals for GliaSite, limited uptake of newer applications, and revenue sensitivity to a small number of customers and physicians.
- An unresolved royalty dispute with the Lawrence Family Trust remains; the parties previously failed to settle, and either may demand binding arbitration. The company also disclosed radioactive-material decommissioning obligations and product-liability exposure, for which it carries insurance.
- The filing reported no material change in previously disclosed risk factors and stated that disclosure controls were effective. The reported quarter included an unusually large allowance-for-doubtful-accounts expense, according to management. The warrant fair-value gain is noncash and model-driven.
Important facts for investors to verify
- Confirm the issuer: the supplied metadata says Perspective Therapeutics, but the filing itself identifies IsoRay, Inc.
- Reconcile any figures used from the MD&A with the financial statements: parts of the supplied MD&A contain operating-loss and net-loss figures that do not match the statements. The summary above uses the financial statements.
- Assess the accessibility and maturity dates of certificates of deposit, operating cash burn, and the assumptions behind management’s five-year liquidity estimate.
- Monitor customer concentration, prostate-market trends, GliaSite adoption and approvals, new-application sales, and the unresolved royalty dispute.